• Saved

September 13, 2022
Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights

Source : https://www.dovepress.com/optimal-choice-of-neoadjuvant-chemotherapy-for-her2-negative-breast-ca-peer-reviewed-fulltext-article-CMAR

Providing evidence that there was no loss of efficacy by administering chemotherapy before surgery enabled investigators to exploit the huge translational research opportunities of the neoadjuvant setting. This in turn paved the way for the contemporary practice-changing clinical trials that are improving breast cancer outcomes for the present generation of patients with breast cancer.


Relevance: In this article we review neoadjuvant clinical trials that guide optimum treatment options for TNBC and HR-positive, HER2-negative breast cancer.

  • September 13, 2022
    Thanks for your input, Albert Dekker ! What new treatments do others suggest for TNBC and HR-positive, HER2-negative breast cancer?
  • September 09, 2022
    few compared newer agents against one the other